AU2008287367B2 - Triazole compounds that modulate HSP90 activity - Google Patents

Triazole compounds that modulate HSP90 activity Download PDF

Info

Publication number
AU2008287367B2
AU2008287367B2 AU2008287367A AU2008287367A AU2008287367B2 AU 2008287367 B2 AU2008287367 B2 AU 2008287367B2 AU 2008287367 A AU2008287367 A AU 2008287367A AU 2008287367 A AU2008287367 A AU 2008287367A AU 2008287367 B2 AU2008287367 B2 AU 2008287367B2
Authority
AU
Australia
Prior art keywords
optionally substituted
nrior
compound
independently
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008287367A
Other languages
English (en)
Other versions
AU2008287367A1 (en
Inventor
Dinesh U. Chimmanamada
Keizo Koya
Hao Li
Teresa Przewloka
Lijun Sun
Weiwen Ying
Shijie Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synta Phamaceuticals Corp
Original Assignee
Synta Phamaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Phamaceuticals Corp filed Critical Synta Phamaceuticals Corp
Publication of AU2008287367A1 publication Critical patent/AU2008287367A1/en
Application granted granted Critical
Publication of AU2008287367B2 publication Critical patent/AU2008287367B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C07F9/6518—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008287367A 2007-08-13 2008-08-13 Triazole compounds that modulate HSP90 activity Ceased AU2008287367B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96444707P 2007-08-13 2007-08-13
US60/964,447 2007-08-13
PCT/US2008/009667 WO2009023211A1 (en) 2007-08-13 2008-08-13 Triazole compounds that modulate hsp90 activity

Publications (2)

Publication Number Publication Date
AU2008287367A1 AU2008287367A1 (en) 2009-02-19
AU2008287367B2 true AU2008287367B2 (en) 2012-02-23

Family

ID=39884398

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008287367A Ceased AU2008287367B2 (en) 2007-08-13 2008-08-13 Triazole compounds that modulate HSP90 activity

Country Status (14)

Country Link
US (3) US8742133B2 (enExample)
EP (1) EP2193135A1 (enExample)
JP (1) JP5596543B2 (enExample)
KR (1) KR20100057030A (enExample)
CN (1) CN101801983B (enExample)
AU (1) AU2008287367B2 (enExample)
BR (1) BRPI0815116A2 (enExample)
CA (1) CA2695995C (enExample)
IL (1) IL203663A (enExample)
MX (1) MX2010001565A (enExample)
NZ (1) NZ583205A (enExample)
TW (1) TWI438199B (enExample)
WO (1) WO2009023211A1 (enExample)
ZA (1) ZA201001064B (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140006070A (ko) 2004-11-18 2014-01-15 신타 파마슈티칼스 코프. Ｈｓｐ90 활성을 조절하는 트리아졸 화합물
EP1934185A1 (en) 2005-08-12 2008-06-25 Synta Pharmaceuticals Corporation Pyrazole compounds that modulate hsp90 activity
US20070250391A1 (en) * 2006-04-05 2007-10-25 Prade Hendrik D Merchandising system and method for food and non-food items for a meal kit
US8063083B2 (en) 2006-05-25 2011-11-22 Synta Pharmaceuticals Corp. Method for treating non-Hodgkin's lymphoma
CA2653217A1 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with protooncogene products
CA2653327A1 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Compounds that modulate hsp90 activity and methods for identifying same
CA2653222A1 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
EP2035396B1 (en) 2006-05-25 2014-05-14 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
CA2677481C (en) 2007-02-08 2015-07-07 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
CN101801983B (zh) * 2007-08-13 2014-01-29 辛塔制药公司 调控hsp90活性的三唑化合物
WO2009139916A1 (en) * 2008-05-16 2009-11-19 Synta Pharmaceuticals Corp. Tricyclic triazole compounds that modulate hsp90 activity
US8450500B2 (en) 2008-06-04 2013-05-28 Synta Pharmaceuticals Corp. Pyrrole compounds that modulate HSP90 activity
WO2009158026A1 (en) 2008-06-27 2009-12-30 Synta Pharmaceuticals Corp. Hydrazonamide compounds that modulate hsp90 activity
WO2010017545A2 (en) 2008-08-08 2010-02-11 Synta Pharamceuticals Corp. Triazole compounds that modulate hsp90 activity
ES2415234T3 (es) * 2008-08-08 2013-07-24 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad Hsp90
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
AU2010308306A1 (en) * 2009-10-19 2012-05-10 Synta Pharmaceuticals Corp. Combination cancer therapy with HSP90 inhibitory compounds
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
US20130156755A1 (en) 2010-04-19 2013-06-20 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
AU2011255438A1 (en) 2010-05-20 2013-01-10 Synta Pharmaceuticals Corp. Method of treating lung adenocarcinoma with Hsp90 inhibitory compounds
US20130172333A1 (en) 2010-05-20 2013-07-04 Synta Pharmaceuticals Corp. Formulation and dosing of hsp90 inhibitory compounds
WO2011149824A1 (en) 2010-05-24 2011-12-01 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
WO2012026433A1 (ja) * 2010-08-23 2012-03-01 第一三共株式会社 三環性ピラゾロピリミジン誘導体のフリー体結晶
US9089570B2 (en) * 2010-09-03 2015-07-28 Tactical Therapeutics Inc Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
WO2012037072A1 (en) 2010-09-13 2012-03-22 Synta Pharmaceuticals Corporation Hsp90 inhibitors for treating non-small cell lung cancers in wild-type egfr and/or kras patients
US20140005145A1 (en) 2010-12-08 2014-01-02 Synta Pharmaceuticals Corp. Combination breast cancer therapy with hsp90 inhibitory compounds
WO2012096919A1 (en) 2011-01-11 2012-07-19 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
EP2678013A1 (en) 2011-02-23 2014-01-01 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with radiotherapy
JP2014507443A (ja) 2011-02-24 2014-03-27 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０阻害化合物での前立腺癌治療
WO2012116247A1 (en) 2011-02-25 2012-08-30 Synta Pharmaceuticals Corp. Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
US20140228418A1 (en) * 2011-05-23 2014-08-14 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mek inhibitors
US20140315943A1 (en) 2011-05-24 2014-10-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors
US20140194388A1 (en) * 2011-05-26 2014-07-10 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with chk inhibitors
AU2012280931A1 (en) 2011-07-07 2014-02-27 Synta Pharmaceuticals Corp. Treating cancer with HSP90 inhibitory compounds
JP2014534228A (ja) * 2011-11-02 2014-12-18 シンタ ファーマシューティカルズ コーポレーション 白金含有剤とｈｓｐ９０阻害剤の組合せ療法
WO2013067162A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
CA2854188A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
CA2868323A1 (en) * 2012-04-04 2013-10-10 Synta Pharmaceuticals Corp. Novel triazole compounds that modulate hsp90 activity
CA2871540A1 (en) 2012-05-10 2013-11-14 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
CN103664910B (zh) * 2012-09-14 2017-07-04 南京大学 含1，4‑苯并二噁烷的1，2，4‑三氮唑类衍生物及其制法与其抗菌活性
KR101941004B1 (ko) 2013-03-25 2019-01-23 주식회사 엘지화학 조절 t 세포로의 분화 유도 및 증식 촉진을 통한 면역 반응 억제용 약학 조성물
JP6497767B2 (ja) 2013-12-16 2019-04-10 日本化薬株式会社 癌治療におけるｈｓｐ９０阻害剤の抗腫瘍効果を予測する方法
BR112017016973A2 (pt) 2015-02-09 2018-04-03 Synta Pharmaceuticals Corp. terapia de combinação de inibidores de hsp90 e inibidores de pd-1 para tratamento de câncer
TN2017000483A1 (en) 2015-05-20 2019-04-12 Amgen Inc Triazole agonists of the apj receptor.
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
MA46827A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj
WO2018097945A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
WO2018093580A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
WO2019089335A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Fused triazole agonists of the apj receptor
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
WO2021119358A1 (en) * 2019-12-10 2021-06-17 Washington University Debaryomyces species as an indicator of non-healing ulcers in crohn's disease
CN113121505B (zh) * 2021-03-02 2023-03-07 中国人民解放军海军军医大学 一种具有抗真菌与抗肿瘤双重作用的三唑酮类化合物及应用
US20240226067A9 (en) * 2021-03-02 2024-07-11 The Johns Hopkins University Anti-fibrotic therapies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060167070A1 (en) * 2004-11-18 2006-07-27 Weiwen Ying Triazole compounds that modulate Hsp90 activity

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU621245B2 (en) * 1989-10-17 1992-03-05 Boehringer Mannheim Gmbh Hydrolase substrates, a process for the preparation thereof and agents containing them
US7329762B2 (en) * 2003-06-12 2008-02-12 Merck & Co., Inc. Prodrugs of mitotic kinesin inhibitors
DE102005007304A1 (de) * 2005-02-17 2006-08-24 Merck Patent Gmbh Triazolderivate
RU2007137133A (ru) * 2005-03-09 2009-04-20 Ниппон Каяку Кабусики Кайся (Jp) Новый ингибитор hsp90
US8399464B2 (en) * 2005-03-09 2013-03-19 Nippon Kayaku Kabushiki Kaisha HSP90 inhibitor
JP5149177B2 (ja) * 2005-07-25 2013-02-20 シンタ ファーマシューティカルズ コーポレーション 増殖性疾患の治療のための、チューブリンポリマー化の１，２，３−トリアゾール系抑制剤
US20070219129A1 (en) * 2005-08-17 2007-09-20 Pritchard Kirkwood A Jr hsp90 decoy peptides and uses thereof
CA2618628C (en) * 2005-08-18 2014-11-18 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
US8629285B2 (en) * 2005-08-18 2014-01-14 Synta Pharmaceuticals Corp. Imidazole compounds that modulate HSP90 activity
AU2007267860B2 (en) * 2006-05-25 2012-08-09 Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity
CA2653222A1 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2007139952A2 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Method for the preparation of triazole compounds with hsp90 modulating activity
EP2035396B1 (en) * 2006-05-25 2014-05-14 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
DE102007002715A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
CN101801983B (zh) 2007-08-13 2014-01-29 辛塔制药公司 调控hsp90活性的三唑化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060167070A1 (en) * 2004-11-18 2006-07-27 Weiwen Ying Triazole compounds that modulate Hsp90 activity

Also Published As

Publication number Publication date
CA2695995C (en) 2015-09-29
TW200911788A (en) 2009-03-16
AU2008287367A1 (en) 2009-02-19
KR20100057030A (ko) 2010-05-28
US8742133B2 (en) 2014-06-03
US9120745B2 (en) 2015-09-01
WO2009023211A1 (en) 2009-02-19
US20110195094A1 (en) 2011-08-11
MX2010001565A (es) 2010-04-27
EP2193135A1 (en) 2010-06-09
TWI438199B (zh) 2014-05-21
IL203663A (en) 2015-08-31
CA2695995A1 (en) 2009-02-19
JP2010536753A (ja) 2010-12-02
NZ583205A (en) 2012-03-30
CN101801983B (zh) 2014-01-29
US20140296186A1 (en) 2014-10-02
CN101801983A (zh) 2010-08-11
US20150366885A1 (en) 2015-12-24
ZA201001064B (en) 2010-10-27
BRPI0815116A2 (pt) 2015-01-27
JP5596543B2 (ja) 2014-09-24

Similar Documents

Publication Publication Date Title
AU2008287367B2 (en) Triazole compounds that modulate HSP90 activity
EP2038262B1 (en) Triazole compounds that modulate hsp90 activity
EP2035396B1 (en) Triazole compounds that modulate hsp90 activity
CA2682665C (en) Triazinone and diazinone derivatives useful as hsp90 inhibitors
AU2007267847B2 (en) Triazole compounds that modulate Hsp90 activity
CA2677481C (en) Triazole compounds that modulate hsp90 activity

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired